Nonclinical data suggest that the cytokine IFNγ plays a pivotal role in the pathogenesis of primary HLH. A massive overexpression of IFNγ leads directly to downstream hypercytokinemia.1,3,4Read more
Gamifant binds to soluble and receptor-bound forms of IFNγ. Binding to IFNγ neutralizes its activity, blocking its intracellular signaling to inhibit macrophage activation and the downstream release of proinflammatory cytokines.1,5-7Read more
Gamifant yielded a 63% overall response rate (ORR) in patients with refractory, recurrent,or progressive disease or who were intolerant of conventional treatment. Seventy percent of patients proceeded to transplant.1See the data
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.4,8-10
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.1
Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1
Gamifant can be ordered through our specialty pharmacy or one of our specialty distributors.